K
Kathy L. Kohlhaas
Researcher at AbbVie
Publications - 23
Citations - 1304
Kathy L. Kohlhaas is an academic researcher from AbbVie. The author has contributed to research in topics: Nicotinic agonist & Agonist. The author has an hindex of 17, co-authored 23 publications receiving 1220 citations. Previous affiliations of Kathy L. Kohlhaas include Abbott Laboratories.
Papers
More filters
Journal ArticleDOI
An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo.
Daniel B. Timmermann,Jens Halvard Grønlien,Kathy L. Kohlhaas,Elsebet Ø. Nielsen,Eva Dam,Tino Dyhring Jorgensen,Philip K. Ahring,Dan Peters,Dorte Holst,Jeppe Kejser Christensen,John Malysz,Clark A. Briggs,Murali Gopalakrishnan,Gunnar M. Olsen +13 more
TL;DR: Data support the notion that α7 nAChR allosteric modulation may constitute a novel pharmacological principle for the treatment of cognitive dysfunction.
Journal Article
Correction to An Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor Possessing Cognition-Enhancing Properties in Vivo
D. B. Timmerman,Jens Halvard Grønlien,Kathy L. Kohlhaas,Elsebet Ø. Nielsen,Eva Dam,Tino Dyhring Jorgensen,Philip K. Ahring,Dan Peters,Dorte Holst,Jeppe Kejser Christensen,John Malysz,Clark A. Briggs,Murali Gopalakrishnan,Gunnar M. Olsen +13 more
Journal ArticleDOI
In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: Preclinical considerations in Alzheimer's Disease
R. Scott Bitner,William H. Bunnelle,Michael W. Decker,Karla Drescher,Kathy L. Kohlhaas,Stella Markosyan,Kennan C. Marsh,Arthur L. Nikkel,Kaitlin E. Browman,Rich Radek,David J. Anderson,Jerry J. Buccafusco,Murali Gopalakrishnan +12 more
TL;DR: The findings show that targeting α7 nAChRs may have potential utility for symptomatic alleviation and slowing of disease progression in the treatment of AD, and expand the understanding of the potential therapeutic viability associated with the α7NAChR approach.
Journal ArticleDOI
eIF2B activator prevents neurological defects caused by a chronic integrated stress response.
Yao Liang Wong,Lauren LeBon,Ana M. Basso,Kathy L. Kohlhaas,Arthur L. Nikkel,Holly M. Robb,Diana Donnelly-Roberts,Janani Prakash,Andrew M. Swensen,Nimrod D. Rubinstein,Swathi Krishnan,Fiona E. McAllister,Nicole V Haste,Jonathon J. O’Brien,Margaret Ann Roy,Andrea T. Ireland,Jennifer M. Frost,Lei Shi,Stephan Riedmaier,Kathleen A. Martin,Michael J. Dart,Carmela Sidrauski +21 more
TL;DR: It is shown that introduction of a human VWM mutation into mice leads to persistent ISR induction in the central nervous system and long-term treatment with a small molecule eIF2B activator, 2BAct, prevents all measures of pathology and normalizes the transcriptome and proteome of VWM mice.
Journal ArticleDOI
Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.
Daniel B. Timmermann,Sandager-Nielsen K,Tino Dyhring,Smith M,Jacobsen Am,E.Ø. Nielsen,Morten Grunnet,Jeppe Kejser Christensen,Dan Peters,Kathy L. Kohlhaas,Gunnar M. Olsen,Philip K. Ahring +11 more
TL;DR: Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors could add a new dimension to the pharmacology and therapeutic approach to these receptors and the novel modulator NS9283 was tested extensively.